Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong · Delayed Price · Currency is HKD 2.535
-0.040 (-1.55%)
Aug 27, 2026, 11:16 AM HKT
HKG:1349 Revenue
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had revenue of 223.17M CNY in the quarter ending June 30, 2026, with 6.18% growth. This brings the company's revenue in the last twelve months to 667.94M, down -3.39% year-over-year. In the year 2025, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had annual revenue of 685.80M, down -3.33%.
Revenue (ttm)
667.94M CNY
Revenue Growth
-3.39%
P/S Ratio
10.03
Revenue / Employee
762.49K CNY
Employees
876
Market Cap
7.73B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 685.80M | -23.61M | -3.33% |
| Dec 31, 2024 | 709.40M | -141.33M | -16.61% |
| Dec 31, 2023 | 850.73M | -180.43M | -17.50% |
| Dec 31, 2022 | 1.03B | -109.15M | -9.57% |
| Dec 31, 2021 | 1.14B | 306.51M | 36.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.